Jiangsu Hengrui Pharma Q3 2026 Earnings: NBMI Coverage Boosts Revenue & Pipeline Growth
Jiangsu Hengrui Pharma’s Q3 earnings, new NBMI drug listings, and a robust oncology pipeline point to rising revenue, higher margins, and future upside.
- JIANGSU HENGRUI PHARMACEUT-H
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
